Toxicity and Outcomes Associated With Reduced-Dose Post-Transplant Cyclophosphamide

Presenter/Author Information

Michael Williams PharmD, BCOP, Transplant and Cellular Therapy, Aurora St. Luke's Medical Center, Advocate HealthFollow
Erin Franzen PharmD, BCOP, Transplant and Cellular Therapy, Aurora St. Luke's Medical Center, Advocate HealthFollow
Shanze Arshad, Transplant and Cellular Therapy, Aurora St. Luke's Medical Center, Advocate Health / University of Kentucky College of Medicine
Brittany Mejaki PharmD, BCOP, Transplant and Cellular Therapy, Aurora St. Luke's Medical Center, Advocate HealthFollow
Syed N. Haider MD, Transplant and Cellular Therapy, Aurora St. Luke's Medical Center, Advocate HealthFollow
Syed A. Abutalib MD, Transplant and Cellular Therapy, Aurora St. Luke's Medical Center, Advocate HealthFollow
Sherjeel Sana MD, Transplant and Cellular Therapy, Advocate Lutheran General Hospital, Advocate HealthFollow
Stephen Medlin DO, Transplant and Cellular Therapy, Inova Schar Cancer InstituteFollow
Zartash Gul MD, Transplant and Cellular Therapy, Inova Schar Cancer InstituteFollow

Recommended Citation

Williams M, Franzen E, Arshad S, et al. Toxicity and Outcomes Associated With Reduced-Dose Post-Transplant Cyclophosphamide. J Patient Cent Res Rev. 2025;12:283-284. doi: 10.17294/2330-0698.2248

Affiliations

Aurora St. Luke's Medical Center, Advocate Lutheran General Hospital

Presentation Notes

Oral presentation at Scientific Day; May 21, 2025; Park Ridge, IL. https://institutionalrepository.aah.org/sciday/2025/judged3/3

Document Type

Abstract